Ocumension Therapeutics (HKSE:01477) Interest Expense : HK$-1.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ocumension Therapeutics's interest expense for the six months ended in Dec. 2023 was HK$ -0.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ocumension Therapeutics's Operating Income for the six months ended in Dec. 2023 was HK$ -194.5 Mil. Ocumension Therapeutics's Interest Expense for the six months ended in Dec. 2023 was HK$ -0.8 Mil. Ocumension Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ocumension Therapeutics Interest Expense Historical Data

The historical data trend for Ocumension Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Interest Expense Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.07

-0.69

-2.00

-1.45

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial						-0.26	-1.15	-0.91	-0.70	-0.75

Ocumension Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.4 Mil.

Ocumension Therapeutics (HKSE:01477) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ocumension Therapeutics's Interest Expense for the six months ended in Dec. 2023 was HK$-0.8 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-194.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$6.2 Mil.

Ocumension Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Ocumension Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines